VIDEO - Future is bio-pharma: Kiran Mazumdar-Shaw


Dr Kiran Mazumdar Shaw, Executive Chairperson, Biocon Ltd and Biocon Biologics is unhappy with the PLI scheme as the Indian pharma industry gains traction post-Covid-19, the government has offered a series of PLI schemes. She says the schemes are skewed towards generic companies.

It does not take into account the higher investment and a longer gestation period that a biopharmaceuticals company needs to give returns on the investment. She feels that biopharmaceuticals—despite it being the future of healthcare—is not getting the recognition it deserves. The schemes are short-sighted.

Follow us on Facebook, Twitter, YouTube & Instagram to never miss an update from Fortune India. To buy a copy, visit Amazon.

Kiran Mazumdar-Shaw Pharma Biocon biopharmaceuticals PLI

Leave a Comment

Your email address will not be published. Required field are marked*

Top Videos